Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AAA 817

Next Previous
Drug Profile

AAA 817

Alternative Names: 225 Actinium PSMA 617; 225 Actinium PSMA 617 - Novartis; 225Ac PSMA 617; AAA-817; Ac-225-PSMA-617

Latest Information Update: 15 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endocyte
  • Developer Endocyte; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Prostate cancer

Most Recent Events

  • 30 Jun 2025 Thomas Hope, University of California, San Francisco plans to initiate a phase I LUTACT trial for Prostate Cancer in the US (IV) (IA) (NCT07054346)
  • 21 Mar 2025 Novartis Pharmaceuticals plans a phase III AcTFirst trial for Prostate cancer (Metastatic disease, Hormone refractory, Combination therapy) in August 2025 (IV) (NCT06855277)
  • 27 Feb 2025 Phase-II/III clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in Singapore (Parenteral) (NCT06780670)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top